Pulmonary Mycobacterium abscessus infection treated in combination with inhaled tigecycline

Andreas Arnholdt Pedersen*, Andreas Fløe, Anders Løkke, Ole Hilberg


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

15 Downloads (Pure)


Pulmonary disease caused by Mycobacterium abscessus is difficult to treat, as there is currently no reliable evidence-based treatment. Treatment is long, complex and has many side effects. In this case, we report a patient with treatment-refractory pulmonary M. abscessus disease, treated with inhaled tigecycline. Treatment with inhaled tigecycline lasted 15 months with comparably limited side effects. There were no positive mycobacterial cultures in the follow-up period of 2 years. Inhaled tigecycline is an option in the treatment of pulmonary M. abscessus when first-line treatment fails. Additional research should investigate this further.

TidsskriftBMJ Case Reports
Udgave nummer12
Antal sider4
StatusUdgivet - 16. dec. 2023

Bibliografisk note

Publisher Copyright:
© 2023 BMJ Publishing Group. All rights reserved.


Dyk ned i forskningsemnerne om 'Pulmonary Mycobacterium abscessus infection treated in combination with inhaled tigecycline'. Sammen danner de et unikt fingeraftryk.